The DOI matches its Crossref record; the references it cites are not checked yet.
LBA-2 Primary analysis of MOUNTAINEER: A phase 2 study of tucatinib and trastuzumab for HER2-positive mCRC
Open accessOverview
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
The MOUNTAINEER study provided the first clinical evidence that dual ERBB2-targeted therapy is superior to monotherapy.
“the MOUNTAINEER study provided the first time clinical evidence of the superiority of dual ERBB2 targeted therapy compared with monotherapy.53”
From Current and emerging concepts for systemic treatment of metastatic colorectal cancer (2025) · cites this paper as [53]
In the phase II MOUNTAINEER study, tucatinib with or without trastuzumab in RAS wild-type, ERBB2-positive metastatic colorectal cancer produced an ORR of 38.1%, median PFS of 8.2 months and median OS of 24.1 months.
“the phase II MOUNTAINEER study53 provided evidence in the largest cohort of patients in comparing ERBB2-specific tyrosine kinase inhibitor tucatinib with or without trastuzumab in RAS wild-type and ERBB2-positive mCRC (ORR 38.1%, mPFS 8.2 months, mOS 24.1 months).”
From Current and emerging concepts for systemic treatment of metastatic colorectal cancer (2025) · cites this paper as [53]
Citations
The citation lists haven’t been fetched yet
References 2 · Cited by 21
Metadata
- Authors
- Strickler, J., Cercek, A., Siena, S., André, T., Ng, K., Van Cutsem, E., Wu, C., Paulson, A., Hubbard, J., Coveler, A., Fountzilas, C., Kardosh, A., Kasi, P., Lenz, H., Ciombor, K., Elez, E., Bajor, D., Stecher, M., Feng, W., & Bekaii-Saab, T.
- Affiliations
- Duke University (US)
- Memorial Sloan Kettering Cancer Center (US)
- University of Milan (IT)
- Hôpital Saint-Antoine (FR)
- Dana-Farber Cancer Institute (US)
- Winship Cancer Institute (US)
- Baylor University Medical Center (US)
- Mayo Clinic (US)
- Seattle Cancer Care Alliance (US)
- Roswell Park Comprehensive Cancer Center (US)
- Oregon Health & Science University (US)
- Weill Cornell Medicine (US)
- USC Norris Comprehensive Cancer Center (US)
- Vanderbilt University Medical Center (US)
- University Hospitals Cleveland Medical Center (US)
- Seagen (United States) (US)
- ORCID
- Venue
- Annals of Oncology
- Publisher
- Elsevier BV
- Published
- 2022-06
- Volume
- 33
- Pages
- S375-S376
- ISSN
- 0923-7534 (ISSN-L)
- OpenAlex
- W4283772784
- Cited by
- 21
- References
- 2
- Citations by year
- 2025: 2 · 2023: 14 · 2022: 5
- FWCI
- 2.20
- Type
- journal article
- Language
- en
- Open access
- bronze
- doi.org
- Licence
- Locations
- Annals of Oncology (publishedVersion)
- Funders
- BeiGene
- Seagen
- Topics
- Health Sciences › Medicine › Oncology › Colorectal Cancer Treatments and Studies
- Health Sciences › Medicine › Oncology › HER2/EGFR in Cancer Research
- Health Sciences › Medicine › Pulmonary and Respiratory Medicine › Lung Cancer Treatments and Mutations
- Keywords
- tucatinib, trastuzumab, HER2 amplification, HER2 overexpression, tyrosine kinase inhibitors, HER2-targeted therapy, RAS/BRAF wild-type
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
